STAT+: Safety-net hospitals take big markups on cancer drugs for commercially insured patients, study finds

Hospitals participating in a federal drug discount program marked up cancer medicines four times for privately insured patients, and often charged cash-paying consumers the same as commercial insurers, a practice that does not “fit the mission” of serving low-income populations, a new analysis found.

Specifically, the median price charged for cancer treatments to commercial insurers or cash-paying patients was 3.8 times what was paid by 123 hospitals participating in the so-called 340B program. Moreover, the hospitals did not reduce prices charged to insurers or patients when their own purchase prices decline, according to the analysis by Moto Bioadvisors, a consulting firm.

Continue to STAT+ to read the full story…

STAT+: Safety-net hospitals take big markups on cancer drugs for commercially insured patients, study finds

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top